{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:30:26Z","timestamp":1778509826345,"version":"3.51.4"},"reference-count":204,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Bradyarrhythmias are an under-recognized component of cancer therapy-related cardiovascular toxicity. As survivorship improves and exposure to targeted and immune therapies increases, clinicians increasingly face clinically relevant sinus node dysfunction and atrioventricular (AV) conduction disease that may interrupt otherwise effective oncologic treatment. We aimed to synthesize evidence on the incidence, phenotype, mechanisms, and management of bradyarrhythmias across major anticancer drug classes. Methods: We performed a narrative review of PubMed and major clinical guidelines, prioritizing prospective trials and large observational cohorts for incidence estimates, and case reports\/series for phenotype and management details. Regulatory prescribing information and pharmacovigilance datasets were consulted to complement trial data. Evidence was organized by drug class and prototypical agents. Results: Bradyarrhythmias ranged from transient sinus bradycardia to high-grade atrioventricular block requiring pacing. The most severe phenotype was associated with immune checkpoint inhibitor-related myocarditis, whereas ALK inhibitors, thalidomide, antimetabolites\u2014particularly 5-fluorouracil\u2014and taxanes showed more reproducible signals for sinus bradycardia. Bradyarrhythmic events were also described with proteasome inhibitors, BTK (Bruton tyrosine kinase) inhibitors, anthracyclines, platinum compounds, high-dose cyclophosphamide, corticosteroids, and other agents, but the strength of evidence varied from regulatory or cohort-based data to isolated case reports. Conclusions: Bradyarrhythmias during cancer therapy are heterogeneous but clinically consequential. Recognition of class-specific patterns, proactive ECG\/electrolyte monitoring, and context-specific management (e.g., drug interruption\/dose modification, pacing when indicated, risk-factor control) can minimize therapy interruption while maintaining oncologic efficacy.<\/jats:p>","DOI":"10.3390\/cancers18101556","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:10:42Z","timestamp":1778505042000},"page":"1556","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bradyarrhythmias Associated with Oncologic Treatment\u2014An Updated Review"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1170-5894","authenticated-orcid":false,"given":"Jakub","family":"St\u0119pie\u0144","sequence":"first","affiliation":[{"name":"Department of Cardiooncology, Medical University of Lodz, 90-647 Lodz, Poland"},{"name":"Department of Cardiology, Nicolaus Copernicus Memorial Hospital, Pabianicka 62, 93-513 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7215-7555","authenticated-orcid":false,"given":"Julita","family":"St\u0119pniak-Bielecka","sequence":"additional","affiliation":[{"name":"Department of Cardiooncology, Medical University of Lodz, 90-647 Lodz, Poland"},{"name":"Department of Cardiology, Nicolaus Copernicus Memorial Hospital, Pabianicka 62, 93-513 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0819-480X","authenticated-orcid":false,"given":"Anna","family":"Cio\u0142ek","sequence":"additional","affiliation":[{"name":"Department of Cardiooncology, Medical University of Lodz, 90-647 Lodz, Poland"},{"name":"Department of Cardiology, Nicolaus Copernicus Memorial Hospital, Pabianicka 62, 93-513 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u0119drzej","family":"Piotrowski","sequence":"additional","affiliation":[{"name":"Department of Cardiooncology, Medical University of Lodz, 90-647 Lodz, Poland"},{"name":"Department of Cardiology, Nicolaus Copernicus Memorial Hospital, Pabianicka 62, 93-513 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Kryca","sequence":"additional","affiliation":[{"name":"Department of Cardiooncology, Medical University of Lodz, 90-647 Lodz, Poland"},{"name":"Department of Cardiology, Nicolaus Copernicus Memorial Hospital, Pabianicka 62, 93-513 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-6437","authenticated-orcid":false,"given":"Grzegorz","family":"Piotrowski","sequence":"additional","affiliation":[{"name":"Department of Cardiooncology, Medical University of Lodz, 90-647 Lodz, Poland"},{"name":"Department of Cardiology, Nicolaus Copernicus Memorial Hospital, Pabianicka 62, 93-513 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/nsmb.3129","article-title":"Structure of Full-Length Human Anti-PD1 Therapeutic IgG4 Antibody Pembrolizumab","volume":"22","author":"Scapin","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/cr.2016.77","article-title":"Structural Basis for Blocking PD-1-Mediated Immune Suppression by Therapeutic Antibody Pembrolizumab","volume":"27","author":"Na","year":"2017","journal-title":"Cell Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus Ipilimumab for Advanced Melanoma: Final Overall Survival Results of a Multicentre, Randomised, Open-Label Phase 3 Study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"ref_5","first-page":"617\u2013619, 625\u2013626","article-title":"Immunotherapeutic Approaches to the Management of Head and Neck Cancer","volume":"32","author":"Nan","year":"2018","journal-title":"Oncology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab Alone or with Chemotherapy versus Cetuximab with Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-048): A Randomised, Open-Label, Phase 3 Study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized Phase III KEYNOTE-045 Trial of Pembrolizumab versus Paclitaxel, Docetaxel, or Vinflunine in Recurrent Advanced Urothelial Cancer: Results of >2 Years of Follow-Up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/ejhf.2289","article-title":"Cardiotoxicity Associated with Immune Checkpoint Inhibitor Therapy: A Meta-Analysis","volume":"23","author":"Castillo","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Retrospective, Pharmacovigilance Study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1093\/eurheartj\/ehab364","article-title":"2021 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy","volume":"42","author":"Glikson","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_13","first-page":"34","article-title":"Complete Heart Block Is a Significant Predictor of Mortality in Immune Checkpoint Inhibitor Myocarditis","volume":"9","author":"Karikalan","year":"2023","journal-title":"CardioOncology"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zotova, L. (2023). Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases. Diagnostics, 13.","DOI":"10.3390\/diagnostics13071243"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.14740\/cr1319","article-title":"Clinical Characteristics and Outcomes in Immune Checkpoint Inhibitor Therapy-Associated Myocarditis","volume":"12","author":"Thakker","year":"2021","journal-title":"Cardiol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/cam4.622","article-title":"Factors Associated with Sinus Bradycardia during Crizotinib Treatment: A Retrospective Analysis of Two Large-Scale Multinational Trials (PROFILE 1005 and 1007)","volume":"5","author":"Ou","year":"2016","journal-title":"Cancer Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2146\/ajhp120261","article-title":"Crizotinib for the Treatment of Non-Small-Cell Lung Cancer","volume":"70","author":"Timm","year":"2013","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"112984","DOI":"10.1016\/j.ejca.2023.112984","article-title":"Efficacy and Safety of Crizotinib in ALK-Positive Systemic Anaplastic Large-Cell Lymphoma in Children, Adolescents, and Adult Patients: Results of the French AcS\u00e9-Crizotinib Trial","volume":"191","author":"Cozic","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1200\/JCO.22.00272","article-title":"Crizotinib in Combination with Chemotherapy for Pediatric Patients with ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children\u2019s Oncology Group Trial ANHL12P1","volume":"41","author":"Lowe","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Choi, J.H. (2025). Inflammatory Myofibroblastic Tumor: An Updated Review. Cancers, 17.","DOI":"10.3390\/cancers17081327"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e26920","DOI":"10.1002\/pbc.26920","article-title":"Crizotinib in ALK+ Inflammatory Myofibroblastic Tumors-Current Experience and Future Perspectives","volume":"65","author":"Theilen","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1056\/NEJMoa1007056","article-title":"Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor","volume":"363","author":"Butrynski","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_23","unstructured":"U.S. Food and Drug Administration (2025, September 20). XALKORI (Crizotinib) Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/202570s033lbl.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/cncr.28040","article-title":"Heart Rate Decrease during Crizotinib Treatment and Potential Correlation to Clinical Response","volume":"119","author":"Ou","year":"2013","journal-title":"Cancer"},{"key":"ref_25","first-page":"1","article-title":"Crizotinib Inhibits Hyperpolarization-Activated Cyclic Nucleotide-Gated Channel 4 Activity","volume":"3","author":"Zhang","year":"2017","journal-title":"CardioOncology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ccr.2011.04.004","article-title":"CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant","volume":"19","author":"Sakamoto","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jaccao.2022.09.006","article-title":"Cardiac Toxicity of Alectinib in Patients with ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up","volume":"5","author":"Pruis","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_29","unstructured":"Genentech USA, Inc., and U.S. Food and Drug Administration (2024). ALECENSA\u00ae (Alectinib) Capsules, Full Prescribing Information 2024."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1470-2045(15)00614-2","article-title":"Activity and Safety of Ceritinib in Patients with ALK-Rearranged Non-Small-Cell Lung Cancer (ASCEND-1): Updated Results from the Multicentre, Open-Label, Phase 1 Trial","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/1078-0432.CCR-14-3157","article-title":"FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer","volume":"21","author":"Khozin","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_32","unstructured":"U.S. Food and Drug Administration (2025, September 27). Zykadia (Ceritinib) Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/205755s016lbl.pdf."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma","volume":"10","author":"Hideshima","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s44313-024-00004-y","article-title":"Real-World Incidence and Risk Factors of Bortezomib-Related Cardiovascular Adverse Events in Patients with Multiple Myeloma","volume":"59","author":"Jang","year":"2024","journal-title":"Blood Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/bjh.14708","article-title":"A Retrospective Analysis of 3954 Patients in Phase 2\/3 Trials of Bortezomib for the Treatment of Multiple Myeloma: Towards Providing a Benchmark for the Cardiac Safety Profile of Proteasome Inhibition in Multiple Myeloma","volume":"178","author":"Laubach","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3349\/ymj.2011.52.1.196","article-title":"Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma","volume":"52","author":"Lee","year":"2011","journal-title":"Yonsei Med. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/1078155210367839","article-title":"Complete Heart Block Secondary to Bortezomib Use in Multiple Myeloma","volume":"17","author":"Dasanu","year":"2011","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_40","first-page":"3456287","article-title":"Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity","volume":"2016","author":"Diwadkar","year":"2016","journal-title":"Case Rep. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"956A","DOI":"10.1016\/j.chest.2018.08.860","article-title":"Lightning Strikes Twice? Alveolar Hemorrhage and Sinus Node Dysfunction Requiring Pacemaker after Initiating Bortezomib for Multiple Myeloma","volume":"154","author":"Bagley","year":"2018","journal-title":"Chest"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"12547","DOI":"10.1182\/blood-2022-166437","article-title":"Bortezomib Induced Peripheral and Severe Autonomic Neuropathy Characterized by Dizziness, Orthostatic Hypotension, and Weight Loss","volume":"140","author":"Jillella","year":"2022","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor Activity of Thalidomide in Refractory Multiple Myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.achaem.2013.08.001","article-title":"Cereblon: Molekularny cel lek\u00f3w immunomoduluj\u0105cych","volume":"44","author":"Jamroziak","year":"2013","journal-title":"Acta Haematol. Pol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12185-016-2073-4","article-title":"Cereblon and Its Downstream Substrates as Molecular Targets of Immunomodulatory Drugs","volume":"104","author":"Ito","year":"2016","journal-title":"Int. J. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5603\/NJO.a2022.0031","article-title":"Principles of Prevention and Management of Adverse Events of Immunomodulatory Drugs in the Treatment of Multiple Myeloma","volume":"72","author":"Vesole","year":"2022","journal-title":"Nowotwory"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.amjcard.2003.12.061","article-title":"Bradycardia during Therapy for Multiple Myeloma with Thalidomide","volume":"93","author":"Fahdi","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"ref_48","first-page":"573","article-title":"Symptomatic Second-Degree Atrioventricular Block due to Thalidomide","volume":"7","author":"Kaya","year":"2016","journal-title":"Ann. Clin. Anal. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s00392-006-0401-z","article-title":"Thalidomide-Induced Symptomatic Third-Degree Atrioventricular Block","volume":"95","author":"Hinterseer","year":"2006","journal-title":"Clin. Res. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ajh.23722","article-title":"Single Agent Lenalidomide Three Times a Week Induces Hematologic Responses in AL Amyloidosis Patients on Dialysis","volume":"89","author":"Lichtman","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1182\/blood-2012-02-413161","article-title":"Activity of Pomalidomide in Patients with Immunoglobulin Light-Chain Amyloidosis","volume":"119","author":"Dispenzieri","year":"2012","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1634\/theoncologist.2009-0274","article-title":"(Pre-)clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor","volume":"15","author":"Hamberg","year":"2010","journal-title":"Oncologist"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/1759-7714.12136","article-title":"Overview of Fundamental Study of Pazopanib in Cancer","volume":"5","author":"Zhao","year":"2014","journal-title":"Thorac. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for Metastatic Soft-Tissue Sarcoma (PALETTE): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial","volume":"379","author":"Blay","year":"2012","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/1074248418769612","article-title":"The Impact of Pazopanib on the Cardiovascular System","volume":"23","author":"Justice","year":"2018","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_58","unstructured":"U.S. Food and Drug Administration (2025, December 02). VOTRIENT (Pazopanib) Tablets, for Oral Use\u2014Full Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/022465s036lbl.pdf."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1111\/1346-8138.14148","article-title":"Acute Intraventricular Conduction Disorder due to Combination Therapy with Dabrafenib and Trametinib for Metastatic Melanoma: Case Report","volume":"45","author":"Yamamura","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e657","DOI":"10.1097\/MJT.0000000000000862","article-title":"Trametinib-Associated Bradycardia","volume":"26","author":"Alhazmi","year":"2019","journal-title":"Am. J. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00280-016-3090-y","article-title":"Phase 1 Study to Evaluate the Effect of the MEK Inhibitor Trametinib on Cardiac Repolarization in Patients with Solid Tumours","volume":"78","author":"Patnaik","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Mohammed, K.A.K., Madeddu, P., and Avolio, E. (2024). MEK Inhibitors: A Promising Targeted Therapy for Cardiovascular Disease. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1404253"},{"key":"ref_64","unstructured":"European Medicines Agency (2025, November 05). Mekinist (Trametinib): EPAR\u2014Product Information. Annex I: Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mekinist-epar-product-information_en.pdf."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer","volume":"353","author":"Procter","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5114\/aoms.2012.28549","article-title":"Cardiac Complications Associated with Trastuzumab in the Setting of Adjuvant Chemotherapy for Breast Cancer Overexpressing Human Epidermal Growth Factor Receptor Type 2\u2014A Prospective Study","volume":"8","author":"Piotrowski","year":"2012","journal-title":"Arch. Med. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1524-4741.2007.00408.x","article-title":"Non-Myopathic Cardiac Events in Two Patients Treated with Trastuzumab","volume":"13","author":"Olin","year":"2007","journal-title":"Breast J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in Previously Treated Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of Atrial Fibrillation Adverse Events Reported in Ibrutinib Randomized Controlled Registration Trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular Toxicities Associated with Ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Zheng, Y., Guo, X., Chen, C., Chi, L., Guo, Z., Liang, J., Wei, L., Chen, X., Ye, X., and He, J. (2023). Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database. Pharmaceuticals, 16.","DOI":"10.3390\/ph16010098"},{"key":"ref_76","first-page":"7304021","article-title":"Profound Sinoatrial Arrest Associated with Ibrutinib","volume":"2017","author":"Mathur","year":"2017","journal-title":"Case Rep. Oncol. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.amjms.2020.11.029","article-title":"Severe Sinus Bradycardia Associated with Ibrutinib: One Rare Case from China","volume":"361","author":"Xu","year":"2021","journal-title":"Am. J. Med. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.hrcr.2021.03.013","article-title":"High-Grade Heart Block Associated with Ibrutinib Therapy","volume":"7","author":"Vartanov","year":"2021","journal-title":"HeartRhythm Case Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.stemcr.2019.03.011","article-title":"Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes","volume":"12","author":"Shafaattalab","year":"2019","journal-title":"Stem Cell Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin Pathways: Pharmacodynamics and Adverse Effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet. Genom."},{"key":"ref_81","first-page":"84","article-title":"Doxorubicin, DNA Torsion, and Chromatin Dynamics","volume":"1845","author":"Yang","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"853","DOI":"10.4103\/0973-1482.139267","article-title":"An Overview of Doxorubicin Formulations in Cancer Therapy","volume":"10","author":"Rivankar","year":"2014","journal-title":"J. Cancer Res. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e005443","DOI":"10.1161\/CIRCEP.117.005443","article-title":"Cancer Treatment-Induced Arrhythmias: Focus on Chemotherapy and Targeted Therapies","volume":"10","author":"Buza","year":"2017","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/01.smj.0000257382.89910.fe","article-title":"Early and Late Arrhythmogenic Effects of Doxorubicin","volume":"100","author":"Kilickap","year":"2007","journal-title":"South. Med. J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/j.hlc.2016.06.301","article-title":"Doxorubicin Induced Complete Heart Block in a Patient without Cardiac Lymphoma","volume":"25","author":"Femia","year":"2016","journal-title":"Heart Lung Circ."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.eupc.2004.12.012","article-title":"Doxorubicin-Induced Second Degree and Complete Atrioventricular Block","volume":"7","author":"Kilickap","year":"2005","journal-title":"Europace"},{"key":"ref_87","first-page":"e26","article-title":"Rare Complication of Doxorubicin-Induced Complete Heart Block in a Patient with Hodgkin\u2019s Lymphoma: A Case Report","volume":"30","author":"Mahadevappa","year":"2023","journal-title":"Eur. J. Hosp. Pharm. Sci. Pract."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-Fluorouracil: Mechanisms of Action and Clinical Strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4103\/0973-1482.37412","article-title":"Transient Asymptomatic Bradycardia in Patients on Infusional 5-Fluorouracil","volume":"3","author":"Talapatra","year":"2007","journal-title":"J. Cancer Res. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e24123","DOI":"10.1200\/JCO.2020.38.15_suppl.e24123","article-title":"Incidence of 5-Fluorouracil Related in Cardiotoxicity in Patients with Head and Neck Cancer","volume":"38","author":"Rajendra","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_91","first-page":"430","article-title":"A Retrospective Study of Cardiotoxicities Induced by 5-Fluouracil (5-FU) and 5-FU Based Chemotherapy Regimens in Pakistani Adult Cancer Patients at Shaukat Khanum Memorial Cancer Hospital & Research Center","volume":"62","author":"Khan","year":"2012","journal-title":"J. Pak. Med. Assoc."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaccao.2020.12.005","article-title":"The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil-Associated Coronary Vasospasm","volume":"3","author":"Zafar","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"184","DOI":"10.18203\/2349-3933.ijam20170108","article-title":"Effect of 5-Fluorouracil on Sinoatrial Node and Conduction System of Heart","volume":"4","author":"Hafeez","year":"2017","journal-title":"Int. J. Adv. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s002770050312","article-title":"Pericarditis Induced by High-Dose Cytosine Arabinoside Chemotherapy","volume":"75","author":"Hermans","year":"1997","journal-title":"Ann. Hematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0145-2126(94)00123-R","article-title":"Cytarabine-Induced Pericarditis: A Case Report and Review of the Literature of the Cardio-Pulmonary Complications of Cytarabine Therapy","volume":"19","author":"Reykdal","year":"1995","journal-title":"Leuk. Res."},{"key":"ref_96","first-page":"1446","article-title":"Cytarabine-Induced Pericarditis Confirmed Using Cardiac MRI: A Case Report","volume":"38","author":"Dong","year":"2021","journal-title":"Echocardiography"},{"key":"ref_97","first-page":"320","article-title":"Sinusal Bradycardia after Receiving Intermediate or High Dose Cytarabine: Four Cases from a Single Institution","volume":"18","author":"Romani","year":"2009","journal-title":"Eur. J. Cancer Care"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Komorowski, L., Fidyt, K., Patkowska, E., and Firczuk, M. (2020). Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage-Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165776"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11886-023-01845-2","article-title":"Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors","volume":"25","author":"Sayegh","year":"2023","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/oncolo\/oyab040","article-title":"FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial","volume":"27","author":"Pulte","year":"2022","journal-title":"Oncologist"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib Efficacy and Safety in Philadelphia Chromosome-Positive Leukemia: Final 5-Year Results of the Phase 2 PACE Trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Jin, Y., Xu, Z., Yan, H., He, Q., Yang, X., and Luo, P. (2020). A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00891"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Mulas, O., Caocci, G., Mola, B., and La Nasa, G. (2021). Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.674748"},{"key":"ref_105","unstructured":"U.S. Food and Drug Administration (2025, November 18). ICLUSIG (Ponatinib) Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/203469s037lbl.pdf."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1016\/S0735-1097(25)04482-1","article-title":"My Heart Skips a Beat Every Time I Am with You","volume":"85","author":"Essarani","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2040620716678118","article-title":"Exploratory Study on the Impact of Switching to Nilotinib in 18 Patients with Chronic Myeloid Leukemia in Chronic Phase with Suboptimal Response to Imatinib","volume":"8","author":"Ailawadhi","year":"2017","journal-title":"Ther. Adv. Hematol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Grela-Wojewoda, A., Pacholczak-Madej, R., Adamczyk, A., Korman, M., and P\u00fcsk\u00fcll\u00fco\u011flu, M. (2022). Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052815"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijcard.2020.05.077","article-title":"Cardiotoxicity of the BCR-ABL1 Tyrosine Kinase Inhibitors: Emphasis on Ponatinib","volume":"316","author":"Singh","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"32042","DOI":"10.1038\/s41598-025-16734-7","article-title":"Triptorelin Associated Adverse Events Evaluated Using FAERS Pharmacovigilance Data","volume":"15","author":"Jia","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/pharma3040026","article-title":"Cardiovascular Adverse Events Associated with Prostate Cancer Treatment: A Disproportionality Analysis from the Food and Drug Administration Adverse Event Reporting System Database","volume":"3","author":"Frey","year":"2024","journal-title":"Pharmacoepidemiology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11523-022-00944-4","article-title":"Relugolix: A Review in Advanced Prostate Cancer","volume":"18","author":"Shirley","year":"2023","journal-title":"Target. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1210\/jc.2015-2770","article-title":"Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (relugolix): Phase 1 Study in Healthy Males","volume":"100","author":"MacLean","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s12032-009-9334-5","article-title":"Tamoxifen and Arrhythmia","volume":"27","author":"Slovacek","year":"2010","journal-title":"Med. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2710.2008.00928.x","article-title":"Tamoxifen-Induced QT Interval Prolongation","volume":"33","author":"Slovacek","year":"2008","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13058-022-01510-6","article-title":"Cellular Mechanisms Underlying Response and Resistance to CDK4\/6 Inhibitors in the Treatment of Hormone Receptor-Positive Breast Cancer","volume":"24","author":"Watt","year":"2022","journal-title":"Breast Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in Combination with Fulvestrant in Women with HR+\/HER2\u2212 Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000519728","article-title":"Second-Degree Type 2 Atrioventricular Block Requiring Permanent Cardiac Pacing in Patients on CDK4\/6 Inhibitors: Report of Two Cases","volume":"17","author":"Cicini","year":"2022","journal-title":"Breast Care"},{"key":"ref_122","first-page":"492","article-title":"Cardiac Safety of Ribociclib Evaluated with 24-Hour Rhythm Holter Electrocardiogram","volume":"32","author":"Yasin","year":"2024","journal-title":"Support. Care Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Shaban, N., Kamashev, D., Emelianova, A., and Buzdin, A. (2023). Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications. Cells, 13.","DOI":"10.3390\/cells13010047"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic Strategies for EGFR-Mutated Non-Small Cell Lung Cancer Patients with Osimertinib Resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Emery, I.F., Battelli, C., Auclair, P.L., Carrier, K., and Hayes, D.M. (2009). Response to Gefitinib and Erlotinib in Non-Small Cell Lung Cancer: A Restrospective Study. BMC Cancer, 9.","DOI":"10.1186\/1471-2407-9-333"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Wang, Y., Qiu, Q., Deng, X., and Wan, M. (2024). EGFR-TKIs\u2014Induced Cardiotoxicity in NSCLC: Incidence, Evaluation, and Monitoring. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1426796"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"104401","DOI":"10.1016\/j.jaccas.2025.104401","article-title":"Unmasking the Heart of Osimertinib: A Closer Look at Drug-Induced Cardiotoxicity","volume":"30","author":"Sabri","year":"2025","journal-title":"JACC Case Rep."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1002\/cncr.27575","article-title":"Phase 1 Dose-Escalation Trial Evaluating the Combination of the Selective MET (mesenchymal-Epithelial Transition Factor) Inhibitor Tivantinib (ARQ 197) plus Erlotinib","volume":"118","author":"Goldman","year":"2012","journal-title":"Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1536\/ihj.22-583","article-title":"Gefitinib Increases the Incidence of QT Prolongation in Patients with Non-Small Cell Lung Cancer","volume":"64","author":"Maimaitituersun","year":"2023","journal-title":"Int. Heart J."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I Inhibitors: Camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic Colorectal Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1002\/cncr.25349","article-title":"Phase 2 Trial of Preoperative Irinotecan plus Cisplatin and Conformal Radiotherapy, Followed by Surgery for Esophageal Cancer","volume":"116","author":"Knox","year":"2010","journal-title":"Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMoa003034","article-title":"Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer","volume":"346","author":"Noda","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s11060-020-03558-w","article-title":"Children with DIPG and High-Grade Glioma Treated with Temozolomide, Irinotecan, and Bevacizumab: The Seattle Children\u2019s Hospital Experience","volume":"148","author":"Crotty","year":"2020","journal-title":"J. Neurooncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e29031","DOI":"10.1002\/pbc.29031","article-title":"Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab for Recurrent Medulloblastoma of Childhood: Report of a COG Randomized Phase II Screening Trial","volume":"68","author":"Levy","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e232053","DOI":"10.1136\/bcr-2019-232053","article-title":"Irinotecan Inducing Sinus Pause Bradycardia in a Patient with Small Round Cell Cancer","volume":"13","author":"Mir","year":"2020","journal-title":"BMJ Case Rep."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jjco\/28.11.709","article-title":"Bradycardia Induced by Irinotecan: A Case Report","volume":"28","author":"Miya","year":"1998","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.1997.15.1.251","article-title":"Phase II Study of Irinotecan in the Treatment of Advanced Colorectal Cancer in Chemotherapy-Naive Patients and Patients Pretreated with Fluorouracil-Based Chemotherapy","volume":"15","author":"Rougier","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S0026-895X(24)12402-9","article-title":"The Mechanism for the Inhibition of Acetylcholinesterases by Irinotecan (CPT-11)","volume":"56","author":"Dodds","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1006\/taap.2001.9293","article-title":"Acetylcholinesterase Blockade Does Not Account for the Adverse Cardiovascular Effects of the Antitumor Drug Irinotecan: A Preclinical Study","volume":"177","author":"Blandizzi","year":"2001","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/sj.bjp.0703766","article-title":"Characterization of a Novel Mechanism Accounting for the Adverse Cholinergic Effects of the Anticancer Drug Irinotecan","volume":"132","author":"Blandizzi","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s13205-023-03636-6","article-title":"Vinca Alkaloids as a Potential Cancer Therapeutics: Recent Update and Future Challenges","volume":"13","author":"Banyal","year":"2023","journal-title":"3 Biotech"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute Lymphoblastic Leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/pbc.24321","article-title":"SIOP PODC: Clinical Guidelines for the Management of Children with Wilms Tumour in a Low Income Setting","volume":"60","author":"Israels","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2014.55.6787","article-title":"Shorter-Duration Therapy Using Vincristine, Dactinomycin, and Lower-Dose Cyclophosphamide with or without Radiotherapy for Patients with Newly Diagnosed Low-Risk Rhabdomyosarcoma: A Report from the Soft Tissue Sarcoma Committee of the Children\u2019s Oncology Group","volume":"32","author":"Walterhouse","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e26677","DOI":"10.1002\/pbc.26677","article-title":"Vincristine-Induced Neuropathy in Pediatric Patients with Acute Lymphoblastic Leukemia in Oman: Frequent Autonomic and More Severe Cranial Nerve Involvement","volume":"64","author":"Nazir","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0379-0738(92)90150-U","article-title":"Sudden Unexpected Death due to Taxus Poisoning. A Report of Five Cases, with Review of the Literature","volume":"56","author":"Visser","year":"1992","journal-title":"Forensic Sci. Int."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","article-title":"How Taxol\/paclitaxel Kills Cancer Cells","volume":"25","author":"Weaver","year":"2014","journal-title":"Mol. Biol. Cell"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/0003-4819-111-4-273","article-title":"Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms","volume":"111","author":"McGuire","year":"1989","journal-title":"Ann. Intern. Med."},{"key":"ref_155","unstructured":"United States Food and Drug Administration (2025, September 10). Paclitaxel Injection, USP, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020262s051lbl.pdf."},{"key":"ref_156","unstructured":"Arbuck, S.G., Strauss, H., Rowinsky, E., Christian, M., Suffness, M., Adams, J., Oakes, M., McGuire, W., Reed, E., and Gibbs, H. (1993). A Reassessment of Cardiac Toxicity Associated with Taxol. J. Natl. Cancer Inst. Monogr., 117\u2013130."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in Cancer Therapy: Molecular Mechanisms of Action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_158","first-page":"218","article-title":"Recurrent Bradycardia Episodes Induced by Cisplatin Infusion","volume":"3","author":"Cabuk","year":"2013","journal-title":"Sak. Med. J."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ijcard.2015.01.013","article-title":"Cisplatin Induced Bradycardia","volume":"182","author":"Darling","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.3892\/ol.2016.4195","article-title":"Bradycardia as a Rare Symptom of Cisplatin Cardiotoxicity: A Case Report","volume":"11","author":"Kucharz","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_161","first-page":"1000151","article-title":"Recurrent Complete Atrioventricular Block during Cisplatin Infusion: A Case Report","volume":"2","author":"Ozcan","year":"2011","journal-title":"J. Clin. Exp. Cardiol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejphar.2017.05.063","article-title":"Cisplatin Induced Arrhythmia; Electrolyte Imbalance or Disturbance of the SA Node?","volume":"811","author":"Oun","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1039\/C4TX00082J","article-title":"The Ex Vivo Neurotoxic, Myotoxic and Cardiotoxic Activity of Cucurbituril-Based Macrocyclic Drug Delivery Vehicles","volume":"3","author":"Oun","year":"2014","journal-title":"Toxicol. Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"154","DOI":"10.34067\/KID.0005622020","article-title":"Hypomagnesemia in the Cancer Patient","volume":"2","author":"Workeneh","year":"2021","journal-title":"Kidney360"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse Large B-Cell Lymphoma (DLBCL): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early Breast Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_167","first-page":"e528","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"HemaSphere"},{"key":"ref_168","first-page":"626","article-title":"Transient, High-Grade Atrioventricular Block from High-Dose Cyclophosphamide","volume":"40","author":"Agarwal","year":"2013","journal-title":"Tex. Heart Inst. J."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0002-8703(94)90686-6","article-title":"Acquired Episodic Complete Heart Block after High-Dose Chemotherapy with Cyclophosphamide and Thiotepa","volume":"127","author":"Ramireddy","year":"1994","journal-title":"Am. Heart J."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/22953337.1985.11719063","article-title":"Transient Heart Block. An Unreported Toxicity of High Dose Chemotherapy with Cyclophosphamide and Etoposide","volume":"40","author":"Sculier","year":"1985","journal-title":"Acta Clin. Belg."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.bmt.1702106","article-title":"Cardiac Conduction Abnormalities in Patients with Breast Cancer Undergoing High-Dose Chemotherapy and Stem Cell Transplantation","volume":"25","author":"Ando","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.rbr.2016.04.009","article-title":"Cyclophosphamide Administration Routine in Autoimmune Rheumatic Diseases: A Review","volume":"57","author":"Teles","year":"2017","journal-title":"Rev. Bras. Reumatol. Engl. Ed."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1042\/CS20150149","article-title":"Cellular and Molecular Effects of the mTOR Inhibitor Everolimus","volume":"129","author":"Saran","year":"2015","journal-title":"Clin. Sci."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for Advanced Pancreatic Neuroendocrine Tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejca.2011.11.027","article-title":"Everolimus in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Patients with 1 or 2 Previous Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies Enrolled in the Phase III RECORD-1 Study","volume":"48","author":"Calvo","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_177","first-page":"196","article-title":"Everolimus as Cancer Therapy: Cardiotoxic or an Unexpected Antiatherogenic Agent? A Narrative Review","volume":"59","author":"Karvelas","year":"2018","journal-title":"Hell. J. Cardiol."},{"key":"ref_178","first-page":"522","article-title":"Trasplante cardiaco y bloqueo auriculoventricular tard\u00edo. Reporte de un caso","volume":"91","author":"Isaza","year":"2021","journal-title":"Arch. Cardiol. Mex."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"103826","DOI":"10.1016\/j.critrevonc.2022.103826","article-title":"Corticosteroids in Oncology: Use, Overuse, Indications, Contraindications. An Italian Association of Medical Oncology (AIOM)\/ Italian Association of Medical Diabetologists (AMD)\/Italian Society of Endocrinology (SIE)\/ Italian Society of Pharmacology (SIF) Multidisciplinary Consensus Position Paper","volume":"180","author":"Faggiano","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"102195","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO Guideline Update for the Prevention of Chemotherapy- and Radiotherapy-Induced Nausea and Vomiting","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jns.2011.07.018","article-title":"Incidence of Various Cardiac Arrhythmias and Conduction Disturbances due to High Dose Intravenous Methylprednisolone in Patients with Multiple Sclerosis","volume":"309","author":"Sahraian","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1365-4632.2004.02587.x","article-title":"Cardiovascular Effects of Corticosteroid Pulse Therapy: A Prospective Controlled Study on Pemphigus Patients","volume":"44","author":"Jain","year":"2005","journal-title":"Int. J. Dermatol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/MPH.0000000000001483","article-title":"Steroid-Induced Bradycardia During Induction Chemotherapy in Children and Young Adults Diagnosed With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma","volume":"41","author":"Duffy","year":"2019","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/raon-2018-0035","article-title":"Pericardial Disease after Breast Cancer Radiotherapy","volume":"53","author":"Marinko","year":"2018","journal-title":"Radiol. Oncol."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Sharifkazemi, M., Elahi, M., and Sayad, M. (2023). Case Report: Early Acute Myocarditis after Radiation Therapy for Breast Cancer: A Case Presentation and Review of Literature. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1020082"},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Gon\u00e7alves, F., and Magalh\u00e3es, M. (2020). Radiotherapy-Induced Acute Myopericarditis. J. Case Rep. Images Oncol.","DOI":"10.5348\/100068Z10FG2020CR"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jacc.2019.07.006","article-title":"Prevention, Diagnosis, and Management of Radiation-Associated Cardiac Disease: JACC Scientific Expert Panel","volume":"74","author":"Desai","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Taunk, N.K., Haffty, B.G., Kostis, J.B., and Goyal, S. (2015). Radiation-Induced Heart Disease: Pathologic Abnormalities and Putative Mechanisms. Front. Oncol., 5.","DOI":"10.3389\/fonc.2015.00039"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/archinte.1981.00340050122029","article-title":"Radiotherapy as a Cause of Complete Atrioventricular Block in Hodgkin\u2019s Disease","volume":"141","author":"Cohen","year":"1981","journal-title":"Arch. Intern. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.crad.2014.08.010","article-title":"MRI Findings of Radiation-Induced Myocardial Damage in Patients with Oesophageal Cancer","volume":"69","author":"Umezawa","year":"2014","journal-title":"Clin. Radiol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jaccao.2024.07.005","article-title":"Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy","volume":"6","author":"Atkins","year":"2024","journal-title":"JACC CardioOncol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1200\/JCO.2004.09.109","article-title":"Cardiovascular Status in Long-Term Survivors of Hodgkin\u2019s Disease Treated with Chest Radiotherapy","volume":"22","author":"Adams","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_193","first-page":"100936","article-title":"Risk of Pacemaker Implantation after Radiotherapy for Breast Cancer: A Study Based on French Nationwide Health Care Database Sample","volume":"38","author":"Errahmani","year":"2022","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.radonc.2016.08.024","article-title":"Risk of Pacemaker or Implantable Cardioverter Defibrillator after Radiotherapy for Early-Stage Breast Cancer in Denmark, 1982\u20132005","volume":"122","author":"Rehammar","year":"2017","journal-title":"Radiother. Oncol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/0284186X.2021.2025265","article-title":"Cardiac Conduction System Exposure with Modern Radiotherapy Techniques for Mediastinal Hodgkin Lymphoma Irradiation","volume":"61","author":"Loap","year":"2022","journal-title":"Acta Oncol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Eastern Cooperative Oncology Group Phase III Clinical Trial of Thalidomide plus Dexamethasone Compared with Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1182\/blood-2004-08-3231","article-title":"The Combination of Thalidomide and Intermediate-Dose Dexamethasone Is an Effective but Toxic Treatment for Patients with Primary Amyloidosis (AL)","volume":"105","author":"Palladini","year":"2005","journal-title":"Blood"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1200\/jco.2009.27.15_suppl.5064","article-title":"Phase Ib Dose Finding Trial of Intravenous Panobinostat with Docetaxel in Patients with Castration-Resistant Prostate Cancer (CRPC)","volume":"27","author":"Rathkopf","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/1078-0432.CCR-23-1796","article-title":"Phase Ia\/b Study of Giredestrant \u00b1 Palbociclib and \u00b1 Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced\/Metastatic Breast Cancer","volume":"30","author":"Jhaveri","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"95.e11","DOI":"10.1016\/j.amjmed.2013.10.003","article-title":"Comparison of 24-Hour Holter Monitoring with 14-Day Novel Adhesive Patch Electrocardiographic Monitoring","volume":"127","author":"Barrett","year":"2014","journal-title":"Am. J. Med."},{"key":"ref_201","first-page":"251","article-title":"Comparison of Arrhythmia Detection by 24-Hour Holter and 14-Day Continuous Electrocardiography Patch Monitoring","volume":"36","author":"Chua","year":"2020","journal-title":"Acta Cardiol. Sin."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1901183","article-title":"Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation","volume":"381","author":"Perez","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2021.08.014","article-title":"ALK Inhibitor-Induced Bradycardia: A Systematic-Review and Meta-Analysis","volume":"161","author":"Cirne","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J. Am. Heart Assoc."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1556\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:31:21Z","timestamp":1778506281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":204,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18101556"],"URL":"https:\/\/doi.org\/10.3390\/cancers18101556","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]}}}